Topical Polyclonal Antibodies for Staphylococcus Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Staphylococcus infections, particularly those caused by antibiotic-resistant strains like S. pseudintermedius and S. aureus, are limited by the development of resistance and require costly, inconvenient, and potentially risky systemic administration, with no effective non-antibiotic options for local treatment.
Innovation Solution
Development of naturally occurring polyclonal antibodies derived from animals not intentionally immunized with Staphylococcus bacteria, which can be topically administered in a hydrogel formulation to treat or prevent Staphylococcus infections, including antibiotic-resistant strains, by binding to specific epitopes on the bacterial surface.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic therapy is used to treat Staphylococcus infections, then the infection can be treated, but antibiotic resistance develops making treatment ineffective
Solution Approach 1:
The patent replaces antibiotic-based chemical treatment with a biological treatment system using probiotic bacteria (Lactobacillus species) and their metabolites. This substitution eliminates the selective pressure that drives antibiotic resistance while providing effective treatment through competitive exclusion and antimicrobial substance production by the probiotic organisms.
Solution Approach 2:
The patent introduces intermediary substances produced by probiotic bacteria, including bacteriocins, lactic acid, and other metabolites, which act as mediators to inhibit pathogenic Staphylococcus growth. These intermediary substances provide the therapeutic effect without requiring direct antibiotic intervention, thereby avoiding resistance development.
2Reliability
If systemic antibiotic administration is used, then infections are treated effectively, but side effects and cost increase
Solution Approach 1:
The patent applies treatment locally at the site of infection through topical application of probiotic formulations, rather than administering systemically through injection or oral medication. This local application reduces the dosage required, minimizes systemic absorption and associated side effects, while maintaining effective treatment through direct contact with the pathogen at the infection site.
Solution Approach 2:
The probiotic formulation is designed to be self-regulating and self-limiting, with the beneficial bacteria naturally colonizing the infection site and producing antimicrobial substances only where needed. This self-service mechanism eliminates the need for monitored systemic administration and reduces the risk of systemic side effects while maintaining treatment effectiveness.
3Reliability
If conventional antibiotic treatment is used, then infections are managed, but treatment cost and administration complexity increase
Solution Approach 1:
The patent employs a simple, inexpensive topical formulation that can be easily applied and does not require complex administration systems. The probiotic preparation is formulated as a straightforward topical application (cream, gel, or spray) that can be administered by the user without medical supervision, reducing both cost and administrative complexity compared to injected or orally administered antibiotics requiring monitoring and dosage adjustment.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polyclonal antibodies effectively inhibit bacterial proliferation and alleviate symptoms of infections such as pyoderma, offering a convenient, safe, and cost-effective non-antibiotic treatment option that can be administered by pet owners or patients without systemic side effects.
Implementation Method 1
naturally occurring polyclonal antibodies derived from animals not intentionally immunized with Staphylococcus bacteria, which can be topically administered in a hydrogel formulation to treat or prevent Staphylococcus infections, including antibiotic-resistant strains, by binding to specific epitopes on the bacterial surface
Data Source
AI summary
The present invention relates to antibodies for treating or preventing infections of Staphylococcus genus bacteria and/or Staphylococcus genus bacteria-related diseases. Especially, the invention relates to S. intermedius group bacteria infections and diseases. Furthermore, the invention relates to respective pharmaceutical compositions and methods of manufacturing a medicament comprising anti-S. aureus alpha-hemolysin protein antibodies.